No 10Y consistency score yet for revenue — the window needs more comparable quarters.
Valuation vs own 10Y history: P/S 0.4x · 10Y median 1.1x · 3rd percentile · as of Oct 5, 2026
Annualized revenue (TTM) · by quarter, last 23
Quarterly YoY revenue growth vs the 20% line
P/S multiple vs its 10Y median
FMP quote market capitalization / revenue from four consecutive issuer fiscal quarters. Quote observation: 2026-10-06T13:20:34.487Z. Latest historical point 2026-10-05. Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.
Current FMP quote-based enterprise value / four-quarter operating income plus matched D&A. Quote observation: 2026-10-06T13:20:34.487Z. Latest historical point 2026-10-05. Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.
FMP quote market capitalization / four-quarter operating cash flow. Quote observation: 2026-10-06T13:20:34.487Z. Latest historical point 2026-10-05. Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.
FMP quote market capitalization / four-quarter operating cash flow less absolute capital expenditures. Quote observation: 2026-10-06T13:20:34.487Z. Latest historical point 2025-10-30. Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.
Unrounded diluted TTM EPS / FMP quote price × 100. Quote observation: 2026-10-06T13:20:34.487Z. Latest historical point 2026-10-05.
Four-quarter operating EBITDA / current FMP quote-based enterprise value × 100. Quote observation: 2026-10-06T13:20:34.487Z. Latest historical point 2026-10-05. Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.
Four-quarter operating cash flow / FMP quote market capitalization × 100. Quote observation: 2026-10-06T13:20:34.487Z. Latest historical point 2026-10-05. Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.
Four-quarter free cash flow / FMP quote market capitalization × 100. Quote observation: 2026-10-06T13:20:34.487Z. Latest historical point 2025-10-30. Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.
The latest delayed quote for Alignment Healthcare, Inc. (ALHC) stock was $8.50 as of Oct 5, 2026, 4:00 PM EDT, up 7.05% from the previous close.
Longer view (total return, dividends reinvested): past 12 months -48.7% · 3-year avg +5.8%/yr · 5-year avg -12.2%/yr
Alignment Healthcare, Inc. is a technology-driven Medicare Advantage provider operating a healthcare platform focused squarely on the consumer.
Medical - Healthcare Plans · Orange, CA
Selected amounts supplied by FMP for each displayed period. Reviewed label references appear where available; other labels are unverified, and items may overlap.
2023-12-31 · USD
Reviewed labels link to their filing; other labels are unverified FMP source labels.
Reviewed presentation labels and parent/child details link to filing evidence; other FMP source labels remain unverified. Mutual exclusivity and reconciliation to a total for the same reporting period and currency have not been verified; percentages and stacked totals are unavailable.
Next Earnings Date
Oct 29, 2026
23 days away
EPS Estimate
-0.02
Revenue Est.
$1.31B
Last Quarter Results
EPS
$0.25
vs Estimate
$0.20
Revenue
| Stock | Market Cap | Close Price | Price Change | TTM Total Return | 5Y CAGR | 10Y CAGR | Compare |
|---|---|---|---|---|---|---|---|
| 1ALHC | $1.76B | $8.50 | +7.05% | -48.69% | -12.15% | N/A | N/A |
| 2NTLA | $1.78B | $12.75 | +4.00% | -35.99% | -37.13% | -3.03% | vs ALHC |
| 3GENB | $1.78B | $13.91 | +1.61% | N/A | N/A | N/A | vs ALHC |
| 4XRAY | $1.71B | $8.56 | -1.27% | -34.07% | -30.27% | -16.38% | vs ALHC |
| 5ASTH | $1.83B | $36.81 | +2.59% | +27.88% | -16.52% | +25.17% | vs ALHC |
| 6KMTS | $1.66B | $28.34 | +3.32% | +14.11% | N/A | N/A | vs ALHC |
6.65
$1.34B
vs Estimate
$1.31B
Consensus Rating
Based on 13 analysts
Average Price Target
$22.23
+161.5% upside
Low
$13.00
Current
$8.50
High
$28.00
Quarterly
| Period | Low | Avg | High | # Analysts |
|---|---|---|---|---|
| Quarter ending Sep 2026 | $-0.02 | $-0.02 | $-0.01 | 4 |
| Quarter ending Dec 2026 | $-0.04 | $-0.02 | $-0.01 | 4 |
| Quarter ending Mar 2027 | $0.10 | $0.10 | $0.10 | 1 |
| Quarter ending Jun 2027 | $0.23 | $0.23 | $0.23 | 1 |
Annual
| Period | Low | Avg | High | # Analysts |
|---|---|---|---|---|
| FY 2026 | $0.16 | $0.18 | $0.20 | 6 |
| FY 2027 | $0.32 | $0.41 | $0.49 | 6 |
Quarterly
| Period | Low | Avg | High | # Analysts |
|---|---|---|---|---|
| Quarter ending Sep 2026 | $1.30B | $1.31B | $1.32B | 8 |
| Quarter ending Dec 2026 | $1.32B | $1.33B | $1.34B | 8 |
| Quarter ending Mar 2027 | $1.54B | $1.55B | $1.57B | 4 |
| Quarter ending Jun 2027 | $1.64B | $1.65B | $1.67B | 5 |
Annual
| Period | Low |
|---|
Source: FMP Analyst Consensus Estimates. Forward P/E uses the consensus EPS estimate for the fiscal year ending Dec 31, 2026, matching Key Metrics.
| Avg |
|---|
| High |
|---|
| # Analysts |
|---|
| FY 2026 | $5.20B | $5.21B | $5.22B | 10 |
| FY 2027 | $6.31B | $6.49B | $6.72B | 10 |
